AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 147 filers reported holding AGIOS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $135,322,777 | -13.4% | 5,467,587 | -0.9% | 0.00% | -25.0% |
| Q2 2023 | $156,314,704 | +25.5% | 5,519,587 | +1.8% | 0.00% | +33.3% |
| Q1 2023 | $124,587,603 | -16.8% | 5,423,927 | +1.7% | 0.00% | -25.0% |
| Q4 2022 | $149,808,934 | +1.4% | 5,335,076 | +2.1% | 0.00% | 0.0% |
| Q3 2022 | $147,766,000 | +28.1% | 5,225,097 | +0.4% | 0.00% | +33.3% |
| Q2 2022 | $115,366,000 | -22.1% | 5,203,701 | +2.3% | 0.00% | -25.0% |
| Q1 2022 | $148,048,000 | -11.1% | 5,085,814 | +0.3% | 0.00% | 0.0% |
| Q4 2021 | $166,605,000 | -33.7% | 5,068,590 | -6.9% | 0.00% | -33.3% |
| Q3 2021 | $251,326,000 | -18.4% | 5,445,821 | -2.6% | 0.01% | -25.0% |
| Q2 2021 | $308,088,000 | +4.1% | 5,590,406 | -2.4% | 0.01% | 0.0% |
| Q1 2021 | $295,914,000 | +21.4% | 5,730,344 | +1.9% | 0.01% | +14.3% |
| Q4 2020 | $243,762,000 | +26.4% | 5,625,713 | +2.1% | 0.01% | +16.7% |
| Q3 2020 | $192,785,000 | -37.3% | 5,508,177 | -4.1% | 0.01% | -45.5% |
| Q2 2020 | $307,237,000 | +52.3% | 5,744,910 | +1.0% | 0.01% | +22.2% |
| Q1 2020 | $201,731,000 | -24.7% | 5,685,804 | +1.4% | 0.01% | 0.0% |
| Q4 2019 | $267,727,000 | +72.5% | 5,606,855 | +17.0% | 0.01% | +50.0% |
| Q3 2019 | $155,234,000 | -32.9% | 4,791,189 | +3.3% | 0.01% | -33.3% |
| Q2 2019 | $231,381,000 | -26.2% | 4,638,769 | -0.2% | 0.01% | -25.0% |
| Q1 2019 | $313,341,000 | +47.0% | 4,646,218 | +0.5% | 0.01% | +20.0% |
| Q4 2018 | $213,119,000 | -35.0% | 4,621,949 | +8.7% | 0.01% | -23.1% |
| Q3 2018 | $327,871,000 | -6.0% | 4,251,439 | +2.7% | 0.01% | -13.3% |
| Q2 2018 | $348,847,000 | +6.6% | 4,141,590 | +3.5% | 0.02% | +7.1% |
| Q1 2018 | $327,155,000 | +73.3% | 4,000,421 | +21.1% | 0.01% | +75.0% |
| Q4 2017 | $188,781,000 | -14.0% | 3,302,096 | +0.4% | 0.01% | -20.0% |
| Q3 2017 | $219,619,000 | +32.8% | 3,290,167 | +2.3% | 0.01% | +25.0% |
| Q2 2017 | $165,401,000 | +9.0% | 3,214,770 | +23.8% | 0.01% | 0.0% |
| Q1 2017 | $151,688,000 | +47.3% | 2,597,391 | +5.2% | 0.01% | +33.3% |
| Q4 2016 | $103,000,000 | -17.5% | 2,468,232 | +4.4% | 0.01% | -14.3% |
| Q3 2016 | $124,879,000 | +41.6% | 2,364,221 | +12.3% | 0.01% | +40.0% |
| Q2 2016 | $88,214,000 | +13.6% | 2,105,591 | +10.1% | 0.01% | 0.0% |
| Q1 2016 | $77,657,000 | -35.8% | 1,912,739 | +2.6% | 0.01% | -37.5% |
| Q4 2015 | $121,012,000 | -80.7% | 1,864,013 | -85.6% | 0.01% | -65.2% |
| Q3 2015 | $627,650,000 | +248.3% | 12,939,906 | +698.0% | 0.02% | +91.7% |
| Q2 2015 | $180,221,000 | +20.4% | 1,621,562 | +2.2% | 0.01% | +20.0% |
| Q1 2015 | $149,685,000 | +3.4% | 1,587,319 | +22.9% | 0.01% | 0.0% |
| Q4 2014 | $144,722,000 | +118.5% | 1,291,702 | +19.7% | 0.01% | +100.0% |
| Q3 2014 | $66,227,000 | +68.3% | 1,079,508 | +25.7% | 0.01% | +66.7% |
| Q2 2014 | $39,345,000 | +33.3% | 858,689 | +13.9% | 0.00% | +50.0% |
| Q1 2014 | $29,511,000 | +401.1% | 753,784 | +206.5% | 0.00% | +100.0% |
| Q4 2013 | $5,889,000 | -22.2% | 245,912 | -9.2% | 0.00% | 0.0% |
| Q3 2013 | $7,569,000 | – | 270,709 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |